
Healthcare
Pfizer Secures Up to $1.5 Billion From Blackstone to Advance Experimental Obesity Treatment
Pfizer has entered into a strategic funding agreement with Blackstone Life Sciences, which could provide up to $1.5 billion through 2028 to support the clinical development of berobenatide, an experimental monthly GLP-1 treatment being studied for chronic weight management and obesity-related conditions.









